Focusing on the tumor microenvironment, OncoResponse garners $40 million for the next stage of the R&D journey
OncoResponse has entered the on-ramp for its immuno-oncology clinical plans. And the biotech now has a $40 million B round from a mix of mainstream and nontraditional investors to get them over the hurdle and into human studies.
The Seattle-based company has spent the last 3 years sorting through prospective antibodies identified through their research of the “elite responders” to checkpoint inhibitors, investigating the antibodies they produce in effectively repelling cancer. That work has been partnered with MD Anderson, which has been providing the tissue samples.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.